News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

San Diego Biotech Pfenex Inc. Slashes Proposed Range To $8 A Share, Eyes $65 Million In IPO Debut


7/18/2014 7:09:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Pfenex, which is developing a biosimilar version of Roche's Lucentis treatment for wet AMD, lowered the proposed price range for its upcoming listing on Thursday. The San Diego, CA-based company still plans to raise $65 million but now plans on offering 8.1 million shares at $8. The company previously filed to offer 5.0 million shares at a price range of $12-$14. At $8, Pfenex now commands a fully diluted market cap of $154 million, 26% below its initial proposed market cap of $207 million.

Help employers find you! Check out all the jobs and post your resume.

Read at Nasdaq
Read at Renaissance Capital

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES